Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Non-Current Liabilities (2019 - 2025)

Historic Other Non-Current Liabilities for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $345000.0.

  • 4D Molecular Therapeutics' Other Non-Current Liabilities fell 1287.88% to $345000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $345000.0, marking a year-over-year decrease of 1287.88%. This contributed to the annual value of $410000.0 for FY2024, which is 1111.11% up from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Other Non-Current Liabilities is $345000.0, which was down 1287.88% from $334000.0 recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Other Non-Current Liabilities high stood at $1.9 million for Q3 2021, and its period low was $212000.0 during Q4 2022.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $345000.0 (2025), whereas its average is $548842.1.
  • In the last 5 years, 4D Molecular Therapeutics' Other Non-Current Liabilities plummeted by 8871.22% in 2022 and then surged by 8018.87% in 2024.
  • Over the past 5 years, 4D Molecular Therapeutics' Other Non-Current Liabilities (Quarter) stood at $214000.0 in 2021, then decreased by 0.93% to $212000.0 in 2022, then soared by 74.06% to $369000.0 in 2023, then increased by 11.11% to $410000.0 in 2024, then dropped by 15.85% to $345000.0 in 2025.
  • Its Other Non-Current Liabilities was $345000.0 in Q3 2025, compared to $334000.0 in Q2 2025 and $322000.0 in Q1 2025.